Diligence memo · auto-generated · as of July 2, 2026

Cupron Inc.

Cupron Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cupron Inc. operates in Biotechnology, based in Richmond.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cupron Inc. has raised $5.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $4.0M on 2010-01-12.

Most recent recorded round closed around 2019-09-03.

Valuation (modeled)modeled

Provath models Cupron Inc. at approximately $78M (range $1.3M–$610M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.21× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era. Within the normal band (121% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 116 months.

Last raise 6.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 46% of Biotechnology peers (4293 compared).

Modeled value ranks above 54% of those peers.

Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.